Are Radiometal-Labeled Antibodies Better Than Iodine-131-Labeled Antibodies: Comparative Pharmacokinetics and Dosimetry of Copper-67-, Iodine-131-, and Yttrium-90-Labeled Lym-1 Antibody in Patients with Non-Hodgkin's Lymphoma

Clinical Lymphoma

Volumn 1, Issue 2, 2000, Pages 118-126

  DeNardo, Gerald L ^a,b   DeNardo, Sally J ^b   O'Donnell, Robert T ^b   Kroger, Linda A ^b   Kukis, David L ^b   Meares, Claude F ^c   Goldstein, Desiree S ^b   Shen, Sui ^b  

^a Molecular Cancer Institute   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Copper 67; Iodine 131; Radiation dosimetry; Radioimmunotherapy; Yttrium 90

Indexed keywords

COPPER; COPPER 67 2IT BAT LYM 1; COPPER-67-2IT-BAT-LYM-1; HETEROCYCLIC COMPOUND; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2IT BAD LYM 1; MONOCLONAL ANTIBODY 2IT-BAD-LYM-1; MONOCLONAL ANTIBODY LYM 1; MONOCLONAL ANTIBODY LYM-1; ORGANOMETALLIC COMPOUND; RADIOACTIVE IODINE; YTTRIUM;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; NONHODGKIN LYMPHOMA; RADIATION DOSE; RADIOIMMUNOTHERAPY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; COPPER RADIOISOTOPES; FEMALE; HETEROCYCLIC COMPOUNDS; HUMANS; IODINE RADIOISOTOPES; LYMPHOMA, NON-HODGKIN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; YTTRIUM RADIOISOTOPES;

EID: 0034280393     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2000.n.010     Document Type: Review

References (58)

1. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993; 328:1023-1030.
2. Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1997.'CA Cancer J Clin 1997; 47:5-27.
3. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996; 14:1974-1981.
4. Press OW, Eary JF, Appelbaum FR, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995; 346:336-340.
5. DeNardo GL, DeNardo SJ, Lamborn KR, et al. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. Cancer Biother Radiopharm 1998; 13:239-254.
6. DeNardo GL, DeNardo SJ, Goldstein DS, et al. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 1998; 16:3246-3256.
7. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:3793-3803.
8. Juweid ME, Stadtmauer E, Hajjar G, et al. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin Cancer Res 1999; 5:3292s-3303s.
9. Kaminski MS, Estes J, Tuck M, et al. Iodine I 131 tositumomab therapy for previously untreated follicular lymphoma (FL). Proc Am Soc Clin Oncol 2000; 19:5a (Abstract #11).
10. DeNardo GL, DeNardo SJ, Kukis DL. et al. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study. Anticancer Res 1998; 18:2779-2788.
11. O'Donnell RT, DeNardo GL, Shen S, et al. A phase I clinical study of 111In/90Y-2IT-BAD-Lym-1 for non-Hodgkin's lymphoma (NHL). J Nucl Med 1999; 40:216.
12. Wilder RB, DeNardo GL, DeNardo SJ. Radioimmunotherapy: recent results and future directions. J Clin Oncol 1996; 14:1383-1400.
13. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995; 36:1902-1909.
14. Brown E, Dairiki JM, Doebler RE, et al. Table of Isotopes. New York: John Wiley, 1978.
15. Mausner LF, Srivastava SC. Selection of radionuclides for radioimmunotherapy. Med Phys 1993; 20:503-509.
16. Press OW, Shan D, Howell-Clark J, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 1996; 56:2123-2129.
17. Novak-Hofer I, Amstutz HP, Macke HR, et al. Cellular processing of copper-67-labeled monoclonal antibody chCE7 by human neuroblastoma cells. Cancer Res 1995; 55:46-50.
18. Mattes MJ, Griffiths GL, Diril H, et al. Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. Cancer 1994; 73:787-793.
19. Naruki Y, Carrasquillo JA, Reynolds JC, et al. Differential cellular catabolism of 111In, 90Y and 125I radiolabeled T101 anti-CD5 monoclonal antibody. Nucl Med Biol 1990; 17:201-207.
20. Smith A, Zangemeister-Wittke U, Waibel R, et al. A comparison of 67Cu-and 131I-labelled forms of monoclonal antibodies SEN7 and SWA20 directed against small-cell lung cancer. Int J Cancer Suppl 1994; 8:43-48.
21. Novak-Hofer I, Zimmermann K, Maecke HR, et al. Tumor uptake and metabolism of copper-67-labeled monoclonal antibody chCE7 in nude mice bearing neuroblastoma xenografts. J Nucl Med 1997; 38:536-544.
22. Smith A, Alberto R, Blaeuenstein P, et al. Preclinical evaluation of 67Cu-labeled intact and fragmented anti-colon carcinoma monoclonal antibody MAb35. Cancer Res 1993; 53:5727-5733.
23. Moi MK, Meares CF, McCall MJ, et al. Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent. Anal Biochem 1985; 148:249-253.
24. Moi MK, Meares CF, DeNardo SJ. The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-Nitrobenzyl)-l,4,7,10-tetraaza-cyclododecane -N,-N′,N″,N‴-tetraacetic acid and study of its yttrium (III) complex. J Am Chem Soc 1988; 110:6266-6267.
25. Kukis DL, Li M, Meares CF.The selectivity of antibody-chelate conjugates for binding copper in the presence of competing metals. Inorganic Chemistry 1993; 32:3981-3982.
26. Kukis DL, DeNardo GL, DeNardo SJ, et al. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res 1995; 55:878-884.
27. Kukis DL, Diril H, Greiner DP, et al. A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates. Cancer 1994; 73:779-786.
28. Kukis DL, DeNardo SJ, DeNardo GL, et al. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates. J Nucl Med 1998; 39:2105-2110.
29. DeNardo SJ, DeNardo GL. Kukis DL, et al. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. J Nucl Med 1999; 40:302-310.
30. DeNardo GL, DeNardo SJ, Shen S, et al. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Nucl Med 1999; 40:1317-1326.
31. Rose LM, Gunasekera AH, DeNardo SJ, et al. Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol Immunother 1996; 43:26-30.
32. McCall MJ, Diril H, Meares CF. Simplified method for conjugating macrocyclic bifunctional chelating agents to antibodies via 2-iminothiolane. Bioconjug Chem 1990; 1:222-226.
33. DeNardo GL, DeNardo SJ, O'Grady LF, et al. Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1. Cancer Res 1990; 50:1014s-1016s.
34. DeNardo DA, DeNardo GL, Yuan A, et al. Prediction of radiation doses from therapy using tracer studies with iodine-131 -labeled antibodies. J Nucl Med 1996; 37:1970-1975.
35. Shen S, DeNardo GL, DeNardo SJ, et al. Reproducibility of operator processing for radiation dosimetry. Nucl Med Biol 1997; 24:77-83.
36. Coffey JL, Watson EE. Calculating dose from remaining body activity: a comparison of two methods. Med Phys 1979; 6:307-308.
37. Loevinger R, Berman M. A revised schema for calculating the absorbed dose from biologically distributed radionuclides. MIRD Pamphlet No. 1. New York: Society of Nuclear Medicine, 1976:1-10.
38. Snyder WS, Ford MR, Warner GG. "S" absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD Pamphlet No. 1I. New York: Society of Nuclear Medicine, 1975:82-83.
39. Shen S, DeNardo GL, O'Donnell RT, et al. Impact of splenomegaly on therapeutic response and I-131 -LYM-1 dosimetry in patients with B-lymphocytic malignancies. Cancer 1997; 80:2553-2557.
40. DeNardo GL, Mahe MA, DeNardo SJ, et al. Body and blood clearance and marrow radiation dose of 131I-Lym-1 in patients with B-cell malignancies. Nucl Med Commun 1993; 14:587-595.
41. Dillman LT, Von der Lage FC. Radionuclide decay schemes and nuclear parameters for use in radiation-dose estimation. MIRD Pamphlet No. 10. New York: Society of Nuclear Medicine, 1975:5-119.
42. Lim SM, DeNardo GL, DeNardo DA, et al. Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources. J Nucl Med 1997; 38:1374-1378.
43. Brodsky A. CRC handbook of radiation measurements and protection, section A volume II: biological and mathematical information. Florida: CRC Press, 1982
44. Deshpande SV, DeNardo SJ, Kukis DL, et al.Yttrium-90-labeled monodonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med 1990; 31:473-479.
45. DeNardo GL, Kroger LA, DeNardo SJ, et al. Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3). Cancer 1994; 73:1012-1022.
46. Denardo SJ, Richman CM, Goldstein DS, et al. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics. dosimetry and initial results in patients with incurable breast cancer. Anticancer Res 1997; 17: 1735-1744.
47. Dasgupta AK, Mausner LF, Srivastava SC. A new separation procedure for Cu-67 from proton irradiated Zn. J Appl Radiat Isot 1991; 42:371-376.
48. Delaloye AB, Delaloye B, Buchegger F, et al. Comparison of copper-67-and iodine-125-labeled anti-CEA monoclonal antibody biodistribution in patients with colorectal tumors. J Nucl Med 1997; 38:847-853.
49. Halpern SE, Hagan PL, Garver PR, et al. Stability, characterization, and kinetics of 111 In-labeled monoclonal antitumor antibodies in normal animals and nude mouse-human tumor models. Cancer Res 1983; 43:5347-5355.
50. Pimm MV, Perkins AC, Baldwin RW Differences in tumour and normal tissue concentrations of iodine- and indium-labelled monoclonal antibody. II. Biodistribution studies in mice with human tumour xenografts. Eur J Nucl Med 1985; 11:300-304.
51. Larson SM, Carrasquillo JA. Advantages of radioiodine over radioindium labeled monodonal antibodies for imaging solid tumors. Nucl Med Biol 1988; 15:231-233.
52. Ellett WH, Humes RM. Absorbed fractions for small volumes containing photon-emitting radioactivity. MIRD Pamphlet No. 8. New York: Society of Nuclear Medicine, 1971:25-32.
53. DeNardo SJ, Jungerman JA, DeNardo GL, et al. The choice of radionudides for radioimmunotherapy. In: Thiessen JW, Paras P, eds. Developing role of short-lived radionuclides in nuclear medical practice. Oak Ridge, TN: DOE Symposium Series, 1985:401-414.
54. United States Nuclear Regulatory Commission Regulatory Guide. Washington, DC: United States Government Printing Office, 1997:1-5.
55. Srivastava SC, Mease RC. Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies. Int J Rad Appl Instrum B 1991; 18:589-603.
56. Smith-Jones PM, Fridrich R, Kaden TA, et al. Antibody labeling with copper-67 using the bifunctional macrocycle 4-[(1,4,8,11-tetraazacydote-tradec-1-yl)methyl]benzoic acid. Bioconjug Chem 1991; 2:415-421.
57. Mirick GR, O'Donnell RT, DeNardo SJ, et al. Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients. Nucl Med Biol 1999; 26:841-845.
58. Volkert WA. Goeckeler WF, Ehrhardt GJ, et al.Therapeutic radionuclides: production and decay property considerations. J Nucl Med 1991; 32:174-185.